The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Open accessAbstract
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and the leading cause of chronic liver disease in the Western world. Twenty per cent of NAFLD individuals develop chronic hepatic inflammation (non-alcoholic steatohepatitis, NASH) associated with cirrhosis, portal hypertension and hepatocellular carcinoma, yet the causes of progression from NAFLD to NASH remain obscure. Here, we show that the NLRP6 and NLRP3 inflammasomes and the effector protein IL-18 negatively regulate NAFLD/NASH progression, as well as multiple aspects of metabolic syndrome via modulation of the gut microbiota. Different mouse models reveal that inflammasome-deficiency-associated changes in the configuration of the gut microbiota are associated with exacerbated hepatic steatosis and inflammation through influx of TLR4 and TLR9 agonists into the portal circulation, leading to enhanced hepatic tumour-necrosis factor (TNF)-α expression that drives NASH progression. Furthermore, co-housing of inflammasome-deficient mice with wild-type mice results in exacerbation of hepatic steatosis and obesity. Thus, altered interactions between the gut microbiota and the host, produced by defective NLRP3 and NLRP6 inflammasome sensing, may govern the rate of progression of multiple metabolic syndrome-associated abnormalities, highlighting the central role of the microbiota in the pathogenesis of heretofore seemingly unrelated systemic auto-inflammatory and metabolic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Either in patients with NASH or animal models, the expression of inflammasome components was increased, indicating the potential role in the pathogenesis of liver injury [226,227,288,289,290,291].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [226]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LPS-mediated activation of KCs via TLR4 leading to MyD88-dependent activation of NF-kB, production of proinflammatory cytokines and subsequent liver injury have also been demonstrated for both MASH(214) and ASH(215).”
From The liver as a central "hub" of the immune system: pathophysiological implications (2025) · cites this paper as [214]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Animal studies have demonstrated a direct role of altered intestinal microbiota in steatosis,15 NASH(16), fibrosis17 and liver cancer.18”
From Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling (2023) · cites this paper as [16]
In the citing paper
“In NAFLD models, lack of inflammasomes has been demonstrated to select a pathogenetic microbiota which was associated with a more severe degree of liver injury [226].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [226]
In the citing paper
“These results indicate that complex interactions between the diet, the innate immunity, bacteria and intestinal function occurs in the development of NASH [226,227], and similar observations were obtained in experimental models of HCC development [285,286,287].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [226]
In the citing paper
“Co-housing wildtype mice with mice prone to MASH led to increased disease severity in wildtype mice, presumably due to a transfer of fecal microbiota (204).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [204]
In the citing paper
“In the MCD diet model, the microbiota has a key role in NASH exacerbation as demonstrated by experiments, in which co-housing transmitted NASH risk and antibiotics reduced NASH risk65.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [65]
In the citing paper
“Functional studies utilizing co-housing and faecal transplantation have provided evidence that dysbiosis is a transmissible driver of liver disease development and progression 65,89.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [65]
In the citing paper
“Similarly, dysbiosis represented a transmissible risk factor in a genetic NASH model in which NASH was triggered by inflammasome deficiency; co-housing of dysbiotic inflammasome-deficient mice with control mice resulted in the development of NASH in control mice65.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [65]
In the citing paper
“Association of bacterial composition with many diseases has been observed, including immune, inflammatory, and metabolic phenotypes.”
From The Gut Microbiome Contributes to a Substantial Proportion of the Variation in Blood Lipids (2015) · cites this paper as [5]
In the citing paper
“Disruption of the murine inflammasomes (see box 1) is associated with an increase in Bacteroidetes and reduction in Firmicutes and results in severe hepatic steatosis and inflammation.41”
From The gut microbiota and host health: a new clinical frontier (2016) · cites this paper as [41]
In the citing paper
“the NLRP6 and NLRP3 inflammasomes may exert protective effects against NAFLD/NASH through modulation of the gut microbiota.181”
From Interaction between microbiota and immunity in health and disease (2020) · cites this paper as [181]
In the citing paper
“Dysbiosis has been observed in mice deficient for inflammasomes components, including NLRP6, ASC, caspase-1, and IL-18 [131,132,133,134].”
From Gut Microbiota and Cancer: From Pathogenesis to Therapy (2019) · cites this paper as [134]
In the citing paper
“The Muc2-KO mouse possesses a distinct gut-associated bacterial community that is influenced by its altered genetic and immune states, as has been shown in other genetic knockout mouse models.4,53–55”
From Using Corticosteroids to Reshape the Gut Microbiome: Implications for Inflammatory Bowel Diseases (2015) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887
Self-citationDesign and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 1×
“Tlr9 –/– mice have been described in another repor”
BackgroundMartinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066
A role for mitochondria in nlrp3 inflammasome activation
Zhou, R., Yazdi, A. S., Menu, P., & Tschopp, J. (2011) · Nature · doi:10.1038/nature09663 · Cited by 5,602
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,728
Thioredoxin-interacting protein links oxidative stress to inflammasome activation
Zhou, R., Tardivel, A., Thorens, B., Choi, I., & Tschopp, J. (2010) · Nature Immunology · doi:10.1038/ni.1831 · Cited by 2,708
Cited by
Sorted by citations
Items 601–700 of 1,011
Functional Flexibility of Intestinal IgA – Broadening the Fine Line
Slack, E. M. C., Balmer, M. L., Fritz, J. H., & Hapfelmeier, S. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00100 · Cited by 103
Butyrate production from high-fiber diet protects against lymphoma tumor
Wei, W., Sun, W., Yu, S., Yang, Y., & Ai, L. (2016) · Leukemia & Lymphoma · doi:10.3109/10428194.2016.1144879 · Cited by 102
Is It Time to Use Probiotics to Prevent or Treat Obesity?
Brusaferro, A., Cozzali, R., Orabona, C., Biscarini, A., Farinelli, E., Cavalli, E., Grohmann, U., Principi, N., & Esposito, S. (2018) · Nutrients · doi:10.3390/nu10111613 · Cited by 106
Association between the gut and oral microbiome with obesity
Benahmed, A. G., Gasmi, A., Doşa, A., Chirumbolo, S., Mujawdiya, P. K., Aaseth, J., Dadar, M., & Bjørklund, G. (2020) · Anaerobe · doi:10.1016/j.anaerobe.2020.102248 · Cited by 102
Targeted delivery of curcumin for treating type 2 diabetes
Maradana, M. R., Thomas, R., & O’Sullivan, B. (2013) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201200791 · Cited by 102
NLRs, inflammasomes, and viral infection
Jacobs, S. R., & Damania, B. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0312132 · Cited by 104
Innate Immune Signaling in Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases
Cai, J., Xu, M. M., Zhang, X., & Li, H. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-013003 · Cited by 101
Skonieczna‐Żydecka, K., Łoniewski, I., Misera, A., Stachowska, E., Maciejewska, D., Marlicz, W. M., & Galling, B. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5102-6 · Cited by 103
Liu, H., Zhan, X., Xu, G., Wang, Z., Li, R., Wang, Y., Qin, Q., Shi, W., Hou, X., Yang, R., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105384 · Cited by 101
Marques, T. M., Wall, R., O’Sullivan, Ó., Fitzgerald, G. F., Shanahan, F., Quigley, E. M. M., Cotter, P. D., Cryan, J. F., Dinan, T. G., Ross, R. P., et al. (2015) · British Journal Of Nutrition · doi:10.1017/s0007114514004206 · Cited by 103
Wang, Z.-B., Xin, S.-S., Ding, L.-N., Ding, W.-Y., Hou, Y.-L., Liu, C.-Q., & Zhang, X.-D. (2019) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2019/3862971 · Cited by 100
The gut microbiota—a clinical perspective on lessons learned
Shanahan, F. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.145 · Cited by 100
Effects of Enteral Nutrition on Crohn’s Disease
Levine, A., & Wine, E. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e3182802acc · Cited by 102
Lade, A. G., Noon, L. A., & Friedman, S. L. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000042 · Cited by 103
The NLRP3 inflammasome in alcoholic and nonalcoholic steatohepatitis
Knorr, J., Wree, A., Tacke, F., & Feldstein, A. E. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1708540 · Cited by 99
Vrieze, A., de Groot, P. F., Kootte, R. S., Knaapen, M., van Nood, E., & Nieuwdorp, M. (2013) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2013.03.003 · Cited by 102
Pan, P., Lam, V., Salzman, N. H., Huang, Y., Yu, J., Zhang, J., & Wang, L. (2017) · Nutrition and Cancer · doi:10.1080/01635581.2017.1340491 · Cited by 99
The Gut-Liver Axis in Cholestatic Liver Diseases
Blesl, A., & Stadlbauer, V. (2021) · Nutrients · doi:10.3390/nu13031018 · Cited by 102
Inulin-type fructans change the gut microbiota and prevent the development of diabetic nephropathy
Luo, L., Luo, J., Cai, Y., Fu, M., Li, W., Shi, L., Liu, J., Dong, R., Xu, X., Tu, L., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106367 · Cited by 101
Integrative inflammasome activity in the regulation of intestinal mucosal immune responses
Elinav, E., Henao‐Mejia, J., & Flavell, R. A. (2012) · Mucosal Immunology · doi:10.1038/mi.2012.115 · Cited by 101
Self-citationGut Microbiota and Lifestyle Interventions in NAFLD
Houghton, D., Stewart, C. J., Day, C. P., & Trenell, M. I. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040447 · Cited by 99
Krawczyk, M. J., Maciejewska, D., Ryterská, K., Czerwińska-Rogowska, M., Jamioł-Milc, D., Skonieczna‐Żydecka, K., Milkiewicz, P., Raszeja‐Wyszomirska, J., & Stachowska, E. (2018) · Nutrients · doi:10.3390/nu10111793 · Cited by 98
Innate Immune Signaling and Its Role in Metabolic and Cardiovascular Diseases
Xu, M. M., Liu, P. P., & Li, H. (2018) · Physiological Reviews · doi:10.1152/physrev.00065.2017 · Cited by 100
Intestinal microbiota: a new force in cancer immunotherapy
Dai, Z., Zhang, J., Wu, Q., Fang, H., Shi, C., Li, Z., Lin, C., Tang, D., & Wang, D. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00599-6 · Cited by 98
The Immunomodulatory Effect of the Gut Microbiota in Kidney Disease
Chi, M., Ma, K., Wang, J., Ding, Z., Li, Y., Zhu, S., Liang, X., Zhang, Q., Song, L., & Liu, C. (2021) · Journal of Immunology Research · doi:10.1155/2021/5516035 · Cited by 103
Okushin, K., Takahashi, Y., Yamamichi, N., Shimamoto, T., Enooku, K., Fujinaga, H., Tsutsumi, T., Shintani, Y., Sakaguchi, Y., Ono, S., et al. (2015) · BMC Gastroenterology · doi:10.1186/s12876-015-0247-9 · Cited by 98
Etienne‐Mesmin, L., Vijay–Kumar, M., Gewirtz, A. T., & Chassaing, B. (2016) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2016.04.007 · Cited by 102
IL-17 Axis Driven Inflammation in Non-Alcoholic Fatty Liver Disease Progression
Giles, D. A., Moreno‐Fernandez, M. E., & Divanovic, S. (2015) · Current Drug Targets · doi:10.2174/1389450116666150531153627 · Cited by 99
HCC Development Is Associated to Peripheral Insulin Resistance in a Mouse Model of NASH
De Minicis, S., Agostinelli, L., Rychlicki, C., Sorice, G. P., Saccomanno, S., Candelaresi, C., Giaccari, A., Trozzi, L., Pierantonelli, I., Mingarelli, E., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097136 · Cited by 97
Jovicic, N. U., Jeftic, I. D., Jovanović, I., Radosavljevic, G. D., Arsenijević, N., Lukić, M. L., & Pejnovic, N. N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134089 · Cited by 97
The Inflammasome in Chronic Complications of Diabetes and Related Metabolic Disorders
Menini, S., Iacobini, C., Vitale, M., & Pugliese, G. (2020) · Cells · doi:10.3390/cells9081812 · Cited by 97
Dubey, S. R., Turnbull, C., Pandey, A., Zhao, A., Kurera, M., Al-Zidan, R. N., Shen, C. X., Gautam, M., Mahajan, S., Jadhav, P. S., et al. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01354-y · Cited by 101
Flass, T., Tong, S., Frank, D. N., Wagner, B. D., Robertson, C. E., Kotter, C. V., Sokol, R. J., Zemanick, E. T., Accurso, F. J., Hoffenberg, E. J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116967 · Cited by 100
Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: An input for novel therapies
Frăsinariu, O. E., Ceccarelli, S., Alisi, A., Moraru, E., & Nobili, V. (2012) · Digestive and Liver Disease · doi:10.1016/j.dld.2012.11.010 · Cited by 99
Federico, A., Dallio, M., Godos, J., Loguercio, C., & Salomone, F. (2015) · Translational research · doi:10.1016/j.trsl.2015.08.002 · Cited by 96
Obesity and the gut microbiome: Striving for causality
Harley, I. T. W., & Karp, C. L. (2012) · Molecular Metabolism · doi:10.1016/j.molmet.2012.07.002 · Cited by 99
Ip, B. C., Hu, K., Liu, C., Smith, D. E., Obin, M. S., Ausman, L. M., & Wang, X. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0178 · Cited by 96
Immune dysregulation in the functional gastrointestinal disorders
Keely, S., Walker, M. M., Marks, E., & Talley, N. J. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12548 · Cited by 96
Gut Microbiota and Complications of Liver Disease
Acharya, C., & Bajaj, J. S. (2017) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2016.09.013 · Cited by 101
Inflammasome: A Double-Edged Sword in Liver Diseases
Luan, J., & Ju, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02201 · Cited by 96
Li, T., Tong, A.-J., Liu, Y.-Y., Huang, Z., Wan, X., Pan, Y., Jia, R., Liu, B., Chen, X., & Zhao, C. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.06.005 · Cited by 97
Zhang, Z., Yuan, Y., Hu, L., Tang, J., Meng, Z., Dai, L., Gao, Y., Ma, S., Wang, X., Yuan, Y., et al. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2022.08.006 · Cited by 96
Oñate, F. P., Chamignon, C., Burz, S. D., Lapaque, N., Monnoye, M., Philippe, C., Bredel, M., Chêne, L., Farin, W., Paillarse, J.-M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512232 · Cited by 97
Ji, G., Wang, Y., Deng, Y., Li, X., & Jiang, Z. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0139-6 · Cited by 97
Jha, P., Claudel, T., Baghdasaryan, A., Mueller, M., Halilbasic, E., Das, S. K., Lass, A., Zimmermann, R., Zechner, R., Höefler, G., et al. (2013) · Hepatology · doi:10.1002/hep.26732 · Cited by 97
Intestinal Microbiota Modulation in Obesity-Related Non-alcoholic Fatty Liver Disease
Porras, D., Nistal, E., Martínez‐Flórez, S., González‐Gallego, J., García‐Mediavilla, M. V., & Sánchez‐Campos, S. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01813 · Cited by 97
Kanda, T., Goto, T., Hirotsu, Y., Masuzaki, R., Moriyama, M., & Omata, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041525 · Cited by 97
Modulation of Short-Chain Fatty Acids as Potential Therapy Method for Type 2 Diabetes Mellitus
Tang, R., & Li, L. (2021) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2021/6632266 · Cited by 96
Time to Consider the “Exposome Hypothesis” in the Development of the Obesity Pandemic
Catalán, V., Avilés-Olmos, I., Rodrı́guez, A., Becerril, S., Fernández‐Formoso, J. A., Kiortsis, D. N., Portincasa, P., Gómez‐Ambrosi, J., & Frühbeck, G. (2022) · Nutrients · doi:10.3390/nu14081597 · Cited by 96
Duseja, A. K., & Chawla, Y. K. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.09.002 · Cited by 97
Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome
Lim, S. K., Taskinen, M., & Borén, J. (2018) · Obesity Reviews · doi:10.1111/obr.12820 · Cited by 99
Microbiota Plays a Key Role in Non-Steroidal Anti-Inflammatory Drug-Induced Small Intestinal Damage
Otani, K., Tanigawa, T., Watanabe, T., Shimada, S., Nadatani, Y., Nagami, Y., Tanaka, F., Kamata, N., Yamagami, H., Shiba, M., et al. (2017) · Digestion · doi:10.1159/000452356 · Cited by 94
Chashmniam, S., Mirhafez, S. R., Dehabeh, M., Hariri, M., Azimi–Nezhad, M., & Gh, B. F. N. M. (2019) · European Journal of Clinical Nutrition · doi:10.1038/s41430-018-0386-5 · Cited by 94
Du, H., Zhao, A., Wang, Q., Yang, X., & Ren, D. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b06571 · Cited by 94
Role of microbiota short-chain fatty acids in the pathogenesis of autoimmune diseases
Rasouli‐Saravani, A., Jahankhani, K., Moradi, S., Gorgani, M., Shafaghat, Z., Mirsanei, Z., Mehmandar‐Oskuie, A., & Mirzaei, R. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114620 · Cited by 98
Gut microbiota and metabolic biomarkers in metabolic dysfunction–associated steatotic liver disease
Long, Q., Luo, F., Li, B., Li, Z., Guo, Z., Chen, Z., Wu, W., & Hu, M. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000310 · Cited by 99
Role of adipose tissue in methionine–choline-deficient model of non-alcoholic steatohepatitis (NASH)
Jha, P., Knopf, A., Köfeler, H. C., Mueller, M., Lackner, C., Höefler, G., Claudel, T., & Trauner, M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.02.012 · Cited by 99
Trivedi, P. J., & Adams, D. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.12.002 · Cited by 98
Regulation of Energy Homeostasis by GPR41
Inoue, D., Tsujimoto, G., & Kimura, I. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00081 · Cited by 97
Chemokines and Chemokine Receptors in the Development of NAFLD
Roh, Y., & Seki, E. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-8684-7_4 · Cited by 94
Bidirectional Role of NLRP3 During Acute and Chronic Cholestatic Liver Injury
Frissen, M., Liao, L., Schneider, K. M., Djudjaj, S., Haybaeck, J., Wree, A., Rolle-Kampczyk, U. E., von Bergen�, M., Latz, E., Boor, P., et al. (2020) · Hepatology · doi:10.1002/hep.31494 · Cited by 93
ACG Clinical Guideline: Malnutrition and Nutritional Recommendations in Liver Disease
Singal, A. K., Wong, R. J., Dasarathy, S., Abdelmalek, M. F., Neuschwander‐Tetri, B. A., Limketkai, B. N., Petrey, J., & McClain, C. J. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003379 · Cited by 93
Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance
Upadhyay, S. K., Eckel‐Mahan, K. L., Mirbolooki, M., Tjong, I. W., Griffey, S. M., Schmunk, G., Koehne, A. L., Halbout, B., Iadonato, S. P., Pedersen, B., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221206110 · Cited by 93
Metagenomic cross-talk: the regulatory interplay between immunogenomics and the microbiome
Levy, M., Thaiss, C. A., & Elinav, E. (2015) · Genome Medicine · doi:10.1186/s13073-015-0249-9 · Cited by 94
Self-citationExendin-4 Protects against Hyperglycemia-Induced Cardiomyocyte Pyroptosis via the AMPK-TXNIP Pathway
Wei, H., Bu, R., Yang, Q., Jia, J., Li, T., Wang, Q., & Chen, Y. (2019) · Journal of Diabetes Research · doi:10.1155/2019/8905917 · Cited by 91
Joshi‐Barve, S., Kirpich, I., Cave, M. C., Marsano, L. S., & McClain, C. J. (2015) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2015.05.006 · Cited by 93
Li, Q., Li, L., Wang, F., Chen, J., Zhao, Y., Wang, P., Nilius, B., Liu, D., & Zhu, Z. (2013) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-013-1274-4 · Cited by 91
Bajaj, J. S., Betrapally, N. S., Hylemon, P. B., Thacker, L. R., Daita, K., Kang, D. J., White, M. B., Unser, A. B., Fagan, A., Gavis, E. A., et al. (2015) · Scientific Reports · doi:10.1038/srep18559 · Cited by 92
Lau, L. H. S., & Wong, S. H. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-8684-7_9 · Cited by 93
Micronutrients in Nonalcoholic Fatty Liver Disease Pathogenesis
Pickett‐Blakely, O., Young, K. A., & Carr, R. M. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.07.004 · Cited by 97
The Role of Myeloid-Derived Cells in the Progression of Liver Disease
Weston, C. J., Zimmermann, H. W., & Adams, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00893 · Cited by 92
A High Protein Calorie Restriction Diet Alters the Gut Microbiome in Obesity
Dong, T. S., Luu, K., Lagishetty, V., Sedighian, F., Woo, S., Dreskin, B. W., Katzka, W. R., Chang, C., Zhou, Y., Arias-Jayo, N., et al. (2020) · Nutrients · doi:10.3390/nu12103221 · Cited by 98
Csák, T., Pillai, A., Ganz, M., Lippai, D., Petrasek, J., Park, J., Kodys, K., Dolganiuc, A., Kurt‐Jones, E. A., & Szabó, G. (2014) · Liver International · doi:10.1111/liv.12537 · Cited by 96
Th17 cells in central nervous system autoimmunity
Sie, C., Korn, T., & Mitsdoerffer, M. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.03.009 · Cited by 95
Interleukin-18 Activates Skeletal Muscle AMPK and Reduces Weight Gain and Insulin Resistance in Mice
Lindegaard, B., Matthews, V. B., Brandt, C., Højman, P., Allen, T. L., Estévez, E., Watt, M. J., Bruce, C. R., Mortensen, O. H., Syberg, S., et al. (2013) · Diabetes · doi:10.2337/db12-1095 · Cited by 93
Role of MicroRNAs in NAFLD/NASH
Szabó, G., & Csák, T. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-4002-4 · Cited by 94
Nonalcoholic Fatty Liver Disease and the Gut Microbiome
Boursier, J., & Diehl, A. M. (2015) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.012 · Cited by 93
Chen, G., Yin, B., Liu, H., Tan, B., Dong, X., Yang, Q., Chi, S., & Zhang, S. (2020) · Aquaculture Research · doi:10.1111/are.14626 · Cited by 90
Mann, J. P., Vito, R. D., Mosca, A., Alisi, A., Armstrong, M. J., Raponi, M., Baumann, U., & Nobili, V. (2015) · Hepatology · doi:10.1002/hep.28374 · Cited by 90
Specific inflammasomes in complex diseases
Masters, S. L. (2012) · Clinical Immunology · doi:10.1016/j.clim.2012.12.006 · Cited by 97
Gut : liver : brain axis: the microbial challenge in the hepatic encephalopathy
Mancini, A., Campagna, F., Amodio, P., & Tuohy, K. M. (2018) · Food & Function · doi:10.1039/c7fo01528c · Cited by 89
Hong, Y., Li, B., Zheng, N., Wu, G., Ma, J., Tao, X., Chen, L., Zhong, J., Sheng, L., & Li, H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00833 · Cited by 89
The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease
Jennison, E., & Byrne, C. D. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0129 · Cited by 91
Beyond the X Factor: Relevance of Sex Hormones in NAFLD Pathophysiology
Torre, S. D. (2021) · Cells · doi:10.3390/cells10092502 · Cited by 91
Watanabe, Y., Nagai, Y., & Takatsu, K. (2013) · Nutrients · doi:10.3390/nu5093757 · Cited by 92
Response of gut microbiota in type 2 diabetes to hypoglycemic agents
Zhang, F., Wang, M., Yang, J., Xu, Q., Liang, C., Chen, B., Zhang, J., Yang, Y., Wang, H., Shang, Y., et al. (2019) · Endocrine · doi:10.1007/s12020-019-02041-5 · Cited by 89
Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?
Ratziu, V., & Friedman, S. L. (2023) · Gastroenterology · doi:10.1053/j.gastro.2020.05.046 · Cited by 88
Gut Microbiota: Association with NAFLD and Metabolic Disturbances
Lau, E., Carvalho, D. M., & Freitas, P. (2015) · BioMed Research International · doi:10.1155/2015/979515 · Cited by 90
Ye, J., Li, Y., Wu, W., Shi, D., Fang, D., Yang, L.-Y., Bian, X., Wu, J., Wáng, Q., Jiang, X., et al. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i23.2468 · Cited by 89
Cencicchio, M. A., Conte, M. L., Sorini, C., & Falcone, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01937 · Cited by 91
Pathak, P., Helsley, R. N., Brown, A. L., Buffa, J. A., Choucair, I., Nemet, I., Baleanu‐Gogonea, C., Gogonea, V., Wang, Z., Garcı́a-Garcı́a, J. C., et al. (2020) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00584.2019 · Cited by 89
Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases
Bruneau, A., Hundertmark, J., Guillot, A., & Tacke, F. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.725390 · Cited by 93
iPSC-derived organ-on-a-chip models for personalized human genetics and pharmacogenomics studies
Palasantzas, V. E. J. M., Tamargo-Rubio, I., Le, K. T. T., Slager, J., Wijmenga, C., Jonkers, I. H., Kumar, V., Fu, J., & Withoff, S. (2023) · Trends in Genetics · doi:10.1016/j.tig.2023.01.002 · Cited by 94
Wu, X., Zhang, F., Xiong, X., Lu, C., Lian, N., Lu, Y., & Zheng, S. (2015) · IUBMB Life · doi:10.1002/iub.1348 · Cited by 88
Singh, R. K. (2016) · SOJ Microbiology & Infectious Diseases · doi:10.15226/sojmid/4/1/00148 · Cited by 89
Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease
Bibbò, S., Ianiro, G., Dore, M. P., Simonelli, C., Newton, E. E., & Cammarota, G. (2018) · Mediators of Inflammation · doi:10.1155/2018/9321643 · Cited by 88
Role of Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease
Cai, J., Zhang, X., & Li, H. (2018) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.08.003 · Cited by 87
Cheng, C., Tan, J., Qian, W., Zhang, L., & Hou, X. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.08.017 · Cited by 86
Innate immune regulatory networks in hepatic lipid metabolism
Bai, L., & Li, H. (2019) · Journal of Molecular Medicine · doi:10.1007/s00109-019-01765-1 · Cited by 86
Gut microbiota and systemic immunity in health and disease
Lo, B. C., Chen, G., Núñez, G., & Caruso, R. (2020) · International Immunology · doi:10.1093/intimm/dxaa079 · Cited by 90
Metadata
- Authors
- Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., Camporez, J.-P., Shulman, G. I., Gordon, J. I., Hoffman, H. M., & Flavell, R. A.
- Affiliations
- Yale University (US)
- Washington University in St. Louis (US)
- Howard Hughes Medical Institute (US)
- University of California San Diego (US)
- Corresponding author
- Flavell, Richard A.
- ORCID
- Venue
- Nature
- Published
- 2012-02
- Volume
- 482
- Issue
- 7384
- Pages
- 179-185
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3276682
- OpenAlex
- W2144275312
- Cited by
- 2,435
- References
- 41
- Citations by year
- 2026: 83 · 2025: 103 · 2024: 137 · 2023: 165 · 2022: 158 · 2021: 182 · 2020: 215 · 2019: 188 · 2018: 197 · 2017: 184 · 2016: 172 · 2015: 195 · 2014: 181 · 2013: 185 · 2012: 85
- FWCI
- 154.13
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Crohn's and Colitis Foundation
- U.S. Public Health Service (K08A1085038)
- National Heart, Lung, and Blood Institute (T32HL007974)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK45735, R01-DK40936, R01DK040936, U24DK059635, R01DK076674, R24DK085638, P30DK045735)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, NLRP3 inflammasome, NLRP6 inflammasome, IL-18, gut dysbiosis, metabolic syndrome, obesity, hepatic steatosis, liver inflammation, TLR4, TLR9, TNF-α, Porphyromonadaceae, host-microbiota interactions, autoinflammatory disease
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Animals, Carrier Proteins, Choline, Colon, Cytoskeletal Proteins, Disease Models, Animal, Fatty Liver, Inflammation, Male, Methionine, Mice, Inbred C57BL, Obesity, Receptors, Cell Surface, RNA, Ribosomal, 16S, Tumor Necrosis Factor-alpha, Disease Progression, Interleukin-18, Apoptosis Regulatory Proteins, Toll-Like Receptor 4, Toll-Like Receptor 9, Mice, CARD Signaling Adaptor Proteins, Metagenome, Inflammasomes, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
